13:17:10 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2022-01-26 Bokslutskommuniké 2021
2021-07-14 Kvartalsrapport 2021-Q2
2021-06-30 Årsstämma 2021
2021-05-27 Ordinarie utdelning NATTO 0.00 NOK
2021-02-17 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-07-15 Kvartalsrapport 2020-Q2
2020-06-22 Ordinarie utdelning NATTO 0.00 NOK
2020-06-19 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-02-19 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning NATTO 0.00 NOK
2019-05-29 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-02-13 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NATTO 0.00 NOK
2018-05-30 Årsstämma 2018
2018-02-08 Bokslutskommuniké 2017
2017-11-24 Extra Bolagsstämma 2017
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-16 Ordinarie utdelning NATTO 0.00 NOK
2017-05-15 Kvartalsrapport 2017-Q1
2017-05-15 Kapitalmarknadsdag 2017
2017-05-15 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-20 Kvartalsrapport 2016-Q1
2016-05-20 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2014-11-26 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-27 Kvartalsrapport 2014-Q1
2014-02-17 Bokslutskommuniké 2013
2013-11-26 Kvartalsrapport 2013-Q3
2013-08-27 Kvartalsrapport 2013-Q2
2013-05-22 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-11-15 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-16 Kvartalsrapport 2012-Q1
2012-02-28 Bokslutskommuniké 2011
2012-02-13 Extra Bolagsstämma 2012
2011-11-17 Kvartalsrapport 2011-Q3
2011-10-31 Extra Bolagsstämma 2011
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-19 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriLäkemedel & Handel
NattoPharma är ett norskt bolag verksamma inom utveckling av läkemedel. Idag innehas störst fokus på utveckling av diverse kosttillskott. Ledande varumärken säljs huvudsakligen via MenaQ7, ett vitamintillskott av K2 karaktär. En stor del av verksamheten fokuserar på forskning och utveckling inom arbetsområdet, vilket sker via separata dotterbolag. Bolaget etablerades 2004 och har sitt huvudkontor i Oslo.
2019-12-03 14:13:00

Oslo, Norway (03 December 2019) - NattoPharma continues to grow in the vitamin K2 industry and to secure working capital for these activities, the board of NattoPharma has discussed with a few select key shareholders to raise funding through a private placement. Pro AS, owned by board member Sjur Thorsheim, and Synergia Life Sciences Pvt. Ltd, a long-time partner of NattoPharma, have decided to increase their shareholding in the company.

Through discussions with the board, the negotiated share price for the transaction is NOK 11,50. After the completion of the private placement of 1 235 000 new shares, Pro As will hold 2 701 310 shares (435 000 new shares) representing 13,91% of the outstanding shares in the company, and Synergia will hold 1 360 000 shares (800 000 new shares) representing 7,00% of the outstanding shares. The net proceeds from the private placement is NOK 14 202 500. The board will use the existing board authorization granted by the Annual General Meeting on May 29[th], 2019.

Further, Pro AS has agreed to extend the maturity of the NOK 6 million loan given to NattoPharma in January 2019 with one year, with other terms and conditions staying the same. The new maturity date is January 7[th], 2021.

The board has considered the Oslo Stock Exchange's guidelines on the rule of equal treatment of shareholders. The board believes that the decision to set aside the existing shareholders' preferential rights to the new shares is the most favorable decision for all shareholders. The company will secure immediate access to capital to strengthen working capital in a period of growth in revenue and increased activity. The negotiated share price is above the average share price in the market for the last months. Also, NattoPharma has over a period of time investigated other avenues of financing, including debt, and concluded that the terms in these arrangements are not favorable and therefore not in the best interest of the other shareholders in the long term.

The new shares will be registered in the Company Register as soon as the Private Placement has been completed, which is expected to be within December 31[st], 2019. The company's Articles of Association will be amended to reflect the new number of shares post completion of the private placement.

XXX

For more information, please contact:

Kjetil Ramsøy

CEO NattoPharma

Email : Kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.